WO2005077395A1 - 生理活性組成物及びその製造方法 - Google Patents
生理活性組成物及びその製造方法 Download PDFInfo
- Publication number
- WO2005077395A1 WO2005077395A1 PCT/JP2005/002824 JP2005002824W WO2005077395A1 WO 2005077395 A1 WO2005077395 A1 WO 2005077395A1 JP 2005002824 W JP2005002824 W JP 2005002824W WO 2005077395 A1 WO2005077395 A1 WO 2005077395A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- genus
- belonging
- composition
- basidiomycetes
- fungi
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to a composition having a physiological activity such as an antitumor effect and a blood glucose lowering effect.
- the present invention relates to a physiologically active living composition containing an extract component of one or more fungi selected from fungi belonging to Basidiomycetes and an extract component of a root of a plant belonging to Aceraceae. .
- compositions comprising an extract derived from several fungi belonging to basidiomycetes and an extract derived from the root of a plant belonging to the Aceraceae family is useful for anti-tumor effect and hyperglycemia in patients with hyperglycemia.
- the present inventors have found that they exhibit an effective oxidation-reduction potential exhibiting a physiological activity such as an effect of lowering the blood pressure (hereinafter, this effect is referred to as a hypoglycemic effect), and completed the present invention.
- a physiology comprising two or more species of basidiomycetes selected from the group consisting of fungi belonging to An active composition.
- the genus Kicoptaceae is Phellinus linteus.
- any one of the above compositions is provided, wherein the agaric bacterium is Agaricus blazei Murill.
- the bacterium belonging to the genus Amanita is Reishi
- composition of any one of the above wherein the composition is Fungus, and the genus Agaricus is Coriolus Versicolor.
- present invention provides any one of the above-mentioned compositions, wherein at least the aforementioned genus bamboo is selected as the basidiomycete.
- any one of the above-mentioned compositions is provided, wherein the plant of the Aceraceae family is a medicinal carrot.
- any one of the above-mentioned compositions wherein the redox potential of the aqueous solution of the composition is 1230 mV or less. Furthermore, in this embodiment, there is also provided a composition wherein the redox potential of an aqueous solution of the composition is 330 mV or less.
- the pH of the aqueous solution of the composition is from 4.5 to 6.5.
- the extract of any of the fruiting body, hypha and culture medium of the basidiomycete and the extract of the root of the Aceraceae plant are each a hot water extract. Either composition is also provided.
- fungi belonging to the basidiomycete Hydrangea aeruginosa Mannaceae belonging to the genus Amanita a bacterium belonging to the genus Asteraceae octopus and the family Asteraceae, a fungus belonging to the basidiomycete agaricaceae agaricaceae and the basidiomycete agaricaceae.
- a method for producing a physiologically active composition comprising a fruiting body and a mycelium of a basidiomycete fungus belonging to the genus Genus Asterinae and / or a fungus belonging to the genus Genus Asterinae. And a step of extracting any of the cultures with hot water, and a fruiting body, mycelium, and culture of a bacterium belonging to the genus Bacillus spp. Belonging to the genus Bacillus spp.
- a method for producing a physiologically active composition comprising a basidiomycete fungus belonging to the genus Genus Asterinae and / or a mycelium of a bacterium belonging to the genus Agaricaceae.
- the extract and the hot water extract of the root of a plant belonging to the Aceraceae family are obtained individually or at least two or more kinds of the hot water extracts are obtained from the same extraction system, and the basidiomycete Hydana-mushrooms, Mennaceae, A hot-water-extracted component of any of the fungi and mycelia of the fungi belonging to the genus Zygomycetes and the fungi belonging to the genus Agaricaceae, and the fungi and fungi belonging to the basidiomycete Agaricaceae Agaricaceae Or a basidiomycete Agaricaceae tobacco.
- a composition containing a hot water extract component of any of the fruiting body, mycelium, and culture of a fungus belonging to the Locus mushroom bamboo spp., And a hot water extract component of the root of the Aceraceae plant A manufacturing method for obtaining a product is provided.
- an extract component obtained from any of the fruiting bodies, mycelia, and cultures (such as culture solutions) of two or more types of bacteria belonging to these genera can be contained as an active ingredient.
- Both bacteria belonging to the genus Amanita and the genus Agaricus may be used, or only one of them may be used.
- Reishi Fungus (Gano derma Lucidum) can be exemplified. Although this fungus naturally grows in trees, it is rare. In addition, artificial cultivation is also possible.
- This bacterium has a shiny, waxy bulk and a shaft, and the length of the shaft can be as large as 15 cm.
- the fruiting body colors are red, blue, yellow, white, purple, and black.
- the fungus grows on stumps and near the base of diseased and weakened trees, forming a white filament.
- Coriolus Versicolor can be exemplified as the genus Agaricus. This fungus is found in western Japan, especially in the Shinshu region (especially in Nagano prefecture), the Shikoku region, Native to the Kyushu region. This fungus is naturally a favorite bacterium, especially prefers hardwoods.
- Mesimakobu As the basidiomycetes belonging to the genus Asterium, Mesimakobu can be mentioned. In particular, in the present invention, it is preferable to use Meshimakobu (Phellinus linteus). Natural mushrooms are woody mushrooms that infest mulberry and produce bright yellow or tan semicircular fruiting bodies. It is said to be mulberry in Chinese medicine.
- Agaricus blazei Murill Japanese name: Kagaritake mushroom
- mushrooms and the like, and preferably Agaricus blazei Murill are used.
- Agaritas brazemuril is an agaric mushroom native to Brazil.
- the bacteria belonging to these basidiomycetes it is preferable to select one or more species from the genus Mannake and the genus Kawatake. More preferably, both the genus Amanita and the genus Kawatake are used, or only the genus Amanita is used. In addition, when selecting one or more species from the genus Amanita and the genus Kawatake, it is preferable to use one or more from the genus Mushrooms and the agaric genus. Both Mushrooms and Agaricus may be used, or either of them may be used. Examples of combinations of various bacteria in Basidiomycetes include the following combinations.
- the fungi belonging to the genus Ganoderma genus, the genus Agaricus, the genus Mesimakop, and the genus Agaricus basidiomycetes may be naturally occurring, artificially cultivated, or obtained by cell culture. Well, there is no particular limitation. Preferably, it is naturally native.
- the form of these fungi used in the present invention may be any of a fruit body, a mycelium and a culture of a fungus body, but is preferably a fruit body.
- the fruiting body is preferably air-dried at room temperature while avoiding light.
- the genus Agaricus is preferably a native fruiting body collected in summer, and more preferably air-dried at room temperature while avoiding light.
- the composition of the present invention also contains an extract component of the root of Aceraceae as an effective component.
- the Aceraceae it is typically ginseng.
- Ginseng includes Panax ginseng C. A. Meyer, American ginseng (P. quinquefolium L.), Ginseng (P. notogings eng), and bamboo ginseng. (Pearl ginseng, P. japonicus C. A. Meyer) and the like.
- Particularly preferred is ginseng. All of these carrots use their roots.
- As the Aceraceae only one kind may be used, or two or more kinds may be used in combination. It should be noted that a plant belonging to the Umbelliferae can be used as a substitute for the Aceraceae plant.
- the composition of the present invention comprises two or more basidiomycetes from the above-mentioned genus Amanita, Agaricus, Asterium and Agaricus, and the roots of the Aceraceae plant in water. It is obtained by extraction using Included in the composition
- the raw material components to be selected are selected based on the already described combinations.
- the extraction may be performed with water at normal temperature, but is preferably performed with hot water.
- the basidiomycete extract component and the Agonaceae extract component may be extracted with hot water for each raw material or in combination of two or more types of raw materials, and the respective extracts may be mixed. Hot water extraction may be performed on the root and the raw material at once.
- all the raw materials of the extraction components to be included in the composition are mixed and extracted with hot water or the like.
- Each raw material is preferably pulverized into a strip or a powder at the time of hot water extraction, and more preferably, broken into strips. In particular, it is preferable to be crushed into small pieces of about 5 mm square or less.
- the mixing ratio of the basidiomycetes to the roots of the Aceraceae plant in the extraction raw material is not particularly limited, but is 0.2 to 20 parts by weight of the roots of the Aceraceae plant to 20 parts by weight of the basidiomycetes. More preferably, it is 1 to 5 parts by weight of the root of the Aceraceae plant to 10 parts by weight of the basidiomycete. More preferably, it is 1 part by weight of the root of the Aceraceae plant to 5 parts by weight of the basidiomycete. It is preferable that two or more basidiomycetes are used in an equal amount.
- the ratios of the above-mentioned extraction raw materials are all ratios in terms of dry matter.
- the amount of basidiomycetes and the amount of roots of Aceraceae plants in each genus may be equal.
- Basidiomycetes Bacillus spp., Agaricus spp., And Betula spp. are used, and when Chixin ginseng is used as the Aceraceae plant, each is used in an equal amount, for example, 4 to 7 g. It can also be extracted with 000 ml of hot water.
- the composition ratio (weight ratio) of Ganoderma lucidum fruiting body: Kawaratake fruiting body: Mesimakobu fruiting body: Chixsetin ginseng (root) is 1: 1: 1: 1.
- a product 6 g of Mannentake fruiting body, 6 g of Masuwaratake fruiting body, 6 g of Meshimakobu fruiting body, Chixeninji 6 g of each powder was collected, mixed, and ground into small pieces of about 5 mm square, 500-1000 ml of distilled water was added to the ground material, and the mixture was boiled for 3 hours using a reflux condenser and filtered. Thereafter, the composition (stock solution) used in the present invention is obtained.
- the temperature of hot water at the time of hot water extraction is from 80 ° C to 100 ° C, preferably from 90 ° C to 95 ° C. Further, the extraction time is preferably at least 1 hour, more preferably 2 hours or more, and further preferably 2.5 hours or more. The upper limit is 3 to 4 hours.
- the extraction operation is preferably performed using a reflux condenser.
- the amount of water with respect to the extraction raw material is not particularly limited, but it is preferable to extract the water with about 500 to 1,000 parts by weight per 10 to 30 parts by weight of the raw material. .
- the extract obtained by extraction at such a weight ratio becomes a liquid having a concentration suitable for administration as it is.
- the remaining extract material is removed from the obtained extract by filtration or the like.
- the filtrate or supernatant of the extract is concentrated as necessary to obtain a concentrated liquid.
- a solid (powder) extractable component is obtained by evaporating water, and a desired dry extractable component is obtained by drying if necessary.
- an additive which stabilizes the formulation or the extracted component can be added at the time of concentration or drying.
- the stock solution of this composition may be appropriately diluted and used as the composition of the present invention.
- the dilution ratio is set as required, but the dilution is generally in the range of 2 to 300 times. Preferably, it is used at a dilution factor of 2 to 20 times, more preferably 4 to 16 times.
- the dilution is not particularly limited, but it is preferable to use water as in the extraction.
- the solvent is removed from this stock solution by an appropriate method, dried and solidified.
- the composition may be obtained by obtaining the extracted component.
- composition can also be constituted as a preparation to be mixed at the time of use. That is, the first agent having an extract component from basidiomycetes and the second agent having an extract component from the roots of Aceraceae can be combined so as to be mixed when used.
- first agent and the second agent may be an aqueous solution or a solid such as a powder.
- the composition prepared in this way has an oxidation-reduction potential of not more than 120 mV in solution.
- one having an oxidation-reduction potential of 900 mV or less is used as the composition of the present invention.
- the oxidation-reduction potential is a value measured in an aqueous solvent, preferably in water.
- the oxidation-reduction potential of the stock solution obtained by the above extraction or the aqueous dilution thereof can be measured as it is.
- the composition is solidified, the measurement is made in a state of being dissolved and suspended in an appropriate solvent or water.
- the redox potential of the solution of the present composition is preferably 330 mV or less, more preferably 300 mv or less, and further preferably 250 mV or less. Most preferably, it is OmV or less. Further, the oxidation-reduction potential is preferably at least 1200 mV, more preferably at least 300 mV.
- the pH of the solution of the present composition is preferably 4.5 or more and 6.5 or less.
- Weak acidity is a pH that is convenient for living cells, because the active ingredient of the present composition functions most effectively.
- the present composition obtained by extracting each extraction raw material with hot water usually has a pH of 4.5 or more and 6.5 or less in the form of a stock solution.
- composition of the present invention does not prevent the composition from containing other active ingredients.
- Other active ingredients can be included as long as they do not prevent synergistic action. Note that these active ingredients may be artificially produced based on the extracted components or their compositions.
- the disclosure of the present invention specifically contemplates active ingredients extracted from natural products, but of course contemplates chemically synthesized active ingredients that exhibit the effects described herein.
- the composition of the present invention has an antitumor activity, particularly an antitumor activity against leukemia, cervical cancer, lung cancer, ovarian cancer, mammary gland cancer (including metastatic cancer), and skin cancer (including metastatic cancer). are doing.
- leukemia erythroblastic leukemia (erythroblastic leukosis) can be exemplified.
- the composition of the present invention can be used as an antitumor agent in mammals such as humans, pests, pests, dogs and cats.
- Anti-tumor activity has been conventionally observed in the extract of Basidiomycetes, and anti-tumor activity has also been confirmed in the extract of ⁇ Cerberidaceae ⁇ .
- the composition of the present invention also has a hypoglycemic effect. This hypoglycemic agent exerts an action in both insulin-dependent diabetes and insulin-dependent diabetes. Furthermore, the composition of the present invention has a blood pressure lowering effect on humans and the like, and can be used as an agent for treating and preventing hypertension. Further, the composition of the present invention has a blood total cholesterol lowering effect and a blood neutral fat lowering effect on humans and the like, and can be used as an agent for treating and preventing hyperlipidemia.
- composition of the present invention is characterized by having no side effects and reducing or eliminating the side effects of other drugs.
- an antitumor agent when used as an antitumor agent, it has various effects such as reduction of pain, improvement of appetite, and good sleep in addition to healing or regression of tumor.
- a hypoglycemic agent in addition to lowering blood sugar levels, it also relieves body pain, especially headaches, Numbness of limbs is greatly improved, appetite is increased, visual acuity is restored, stress is reduced, and sleep is comfortable.
- the basidiomycete extract component and the Acerutaceae extract component which are the active ingredients in the present invention, are mixed with a pharmaceutically acceptable carrier or additive and used as a composition in a form suitable for administration.
- a pharmaceutically acceptable carrier or additive No particular limitation is imposed on the form of the composition.
- Liquid solutions, syrups, suspensions, powders, granules, tablets, pills, capsules, emulsions, troches, chewables, suppositories, eye drops, injections, aerosols It can be formulated as an elixir or the like. It is also preferable to add water at the time of use to make a solid (powder) agent capable of recovering a liquid material.
- composition of the present invention can be administered orally or parenterally. Preferably, it is administered orally.
- the general dosage for oral administration is shown below.
- the dose is appropriately set according to the symptoms, physical strength of the individual, and the like. That is, as a general dose (normal dose), for example, the extract component from 200 mg to 2 g of basidiomycetes and 100 mg to lg of the roots of Aceraceae per 1 kg of body weight is taken as a daily dose. It is administered in three divided doses.
- the ratio be 0.25 to 0.35 g of the extract component per kg of basidiomycete and Aceraceae plant / kg body weight per day.
- an extract component from 0.12 to 0.18 g of basidiomycetes and 0.12 g of the roots of Aceraceae plants to Zkg body weight day.
- a hypoglycemic agent it is preferable to involve the administration of a water and / or alcohol extract of the roots of Aceraceae plants.
- the alcohol extract is obtained by using the roots of Aceraceae plants, preferably medicinal carrots, more preferably chixen ginseng, in the form of small pieces or powder (preferably, small pieces of about 5 mm square). For example, for 10 to 20 parts by weight of the strips, add 300 to 600 parts by weight of a 40% ethyl alcohol solution, and add this solution at 80 to 100 ° C until the alcohol is almost completely evaporated. By heating and extracting Can be obtained.
- composition of the present invention Since the composition of the present invention has extremely low toxicity and does not exhibit significant side effects, it can be safely administered even at a high dose depending on the symptoms.
- the preferred dosage form for oral administration is a liquid or syrup. Further, the medium is preferably water.
- Formulation Solution 1 As shown in Table 2, the redox potentials of Formulation Solution 1 (RKGME), Formulation Solution 2 (RKGA), Formulation Solution 3 (RMEG), and Formulation Solution 4 (RAG) were characteristic.
- the redox potentials of Formulation Solution 1 and Formulation Solution 3 containing the extract of Mesimakobu showed an approximately constant value over time.
- Formulation Solution 2 and Formulation Solution 4 containing the agaricus extract component the oxidation-reduction potential was significantly reduced.
- the redox potential of Formulation Solution 5 (RKG) decreased with the passage of time, but the decrease was approximately intermediate between the system containing the extract of Meshimakop and the system containing the extract of agaritas.
- formulation liquid 6 (Mesima The oxidation-reduction potential of Kobu single extract was stable, and the redox potential of Formulation solution 7 (agalitas single extract) was significantly reduced. From the above, the time-dependent changes in the redox potentials of the prescription solutions 1 and 3 containing meshimakob and the prescription solutions 2 and 4 containing agaritas were, respectively, the prescription solution 6 (meshimakobu single extract) and the prescription solution 7 ( It can be said that it corresponds to the change with time of the oxidation-reduction potential of Agaricus aliquot.
- the pH was approximately stable in all the formulations.
- the pH at the time of preparation of the formulation liquid was in the range of 4.5 to 6.0 for the formulation liquids 1 to 4, was weakly acidic, and was maintained throughout the storage period.
- the present inventor has confirmed that the prescription liquid 5 (RKG) has an antitumor effect, a blood glucose lowering effect, and a cholesterol lowering effect, and its physiological activity has a redox potential of 330 mV or less.
- US Pat. No. 6,746,675 US Pat. No. 6,746,675
- Formulations 1-4 can maintain their redox potential at least against the passage of time (in other words, against oxidation) without significantly increasing the reduced redox potential. It is considered to indicate the reducing power of the formulation.
- Formulation solutions 1 to 4 are weakly acidic, do not damage living cells, and have an oxidation-reduction potential of 330 mV or less during solution preparation. It was found that it had a physiological activity such as
- a hot water extract of basidiomycete and a hot water extract of the root of a plant belonging to the Aceraceae family were used, but other compositions are also contemplated.
- components can be extracted from natural products by other extraction methods.
- the starting material is subjected to an extraction process, and the extracted components are filtered and evaporated under reduced pressure.
- the product is sterilized, dried and then sieved to a powder.
- the dried extract is made into powders, granules, capsules, tablets and the like.
- the extracted components are mixed with a binder, granulated, dried and formed into granules.
- the granules may be used as they are, tableted, or filled in capsules.
- Additional binder can be added either before or after the granulation step of the extracted components after drying.
- the extracted component can be dried and filled into a capsule to encapsulate the same.
- additives can be added. Additives can include, but are not limited to, one or more preservatives to extend the half-life of the component.
- the active ingredient can be dissolved in a pharmaceutically acceptable solvent, filtered, and filled into an ampoule. These ampules can be sterilized.
- other pharmaceutically acceptable additives can be added to the solution. Additives can include, but are not limited to, one or more preservatives to extend the half-life of the component.
- the active ingredient can be separated, and only the separated active ingredient can be used as a therapeutic agent.
- the active ingredient can be identified and produced chemically.
- the chemically synthesized active ingredient can be used in powders, granules, capsules, tablets, ampoules and the like to provide another vehicle for administering the composition to a patient.
- other effective pharmaceutically acceptable additives can be added as needed.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK05710527.2T DK1736206T3 (da) | 2004-02-16 | 2005-02-16 | Fysiologisk aktiv sammensætning og fremgangsmåde til fremstilling af denne |
EP05710527A EP1736206B1 (en) | 2004-02-16 | 2005-02-16 | Physiologically active composition and process for producing the same |
US10/589,357 US20070178118A1 (en) | 2004-02-16 | 2005-02-16 | Physiologically active composition and preparing method thereof |
AT05710527T ATE529119T1 (de) | 2004-02-16 | 2005-02-16 | Physiologisch wirksame zusammensetzung und verfahren zu ihrer herstellung |
JP2005518074A JPWO2005077395A1 (ja) | 2004-02-16 | 2005-02-16 | 生理活性組成物及びその製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004038443 | 2004-02-16 | ||
JP2004-038443 | 2004-02-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005077395A1 true WO2005077395A1 (ja) | 2005-08-25 |
Family
ID=34857807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/002824 WO2005077395A1 (ja) | 2004-02-16 | 2005-02-16 | 生理活性組成物及びその製造方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20070178118A1 (ja) |
EP (1) | EP1736206B1 (ja) |
JP (1) | JPWO2005077395A1 (ja) |
CN (1) | CN1921871A (ja) |
AT (1) | ATE529119T1 (ja) |
DK (1) | DK1736206T3 (ja) |
ES (1) | ES2372696T3 (ja) |
WO (1) | WO2005077395A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO20014256D0 (no) | 2001-09-03 | 2001-09-03 | Bjoern Kristiansen | Fremstilling av immunstimulerende forbindelse |
US7514085B2 (en) * | 2004-07-16 | 2009-04-07 | Medimush A/S | Immune modulating compounds from fungi |
CN101396424B (zh) * | 2008-07-30 | 2010-12-22 | 刘超 | 一种治疗和预防心脑血管疾病的药物组合物及其制备方法 |
EP2468253A1 (en) | 2010-12-14 | 2012-06-27 | InterMed Discovery GmbH | Terpenoid spiro ketal compounds with LXR agonists activity, their use and formulations with them |
CN102397302A (zh) * | 2011-11-18 | 2012-04-04 | 四川省南充绿宝菌业科技有限公司 | 天然桑黄与原木赤灵芝活性物质提取物的生产方法及产品 |
CN113616737A (zh) * | 2021-07-29 | 2021-11-09 | 山东臻稀生物科技有限公司 | 一种抗肿瘤且低毒无副作用的稀土多菌糖中药组方 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11292786A (ja) * | 1998-04-10 | 1999-10-26 | Tadashi Goino | 抗腫瘍活性を有する薬剤 |
JP2000143526A (ja) * | 1998-11-13 | 2000-05-23 | Asuke Yakuhin Kk | 田七人参、霊芝、アガリクス茸を主成分とする糖尿・高血圧・肝機能改善剤およびこれの製造方法 |
WO2001056589A2 (en) * | 2000-01-31 | 2001-08-09 | Tadashi Goino | Physiologically active compositions of basidiomycotina and araliaceae extracts |
JP2002000229A (ja) * | 2000-06-23 | 2002-01-08 | S F C:Kk | 健康食品 |
JP2002235084A (ja) * | 2001-02-08 | 2002-08-23 | Ishikawa Tennen Yakko Busshitsu Kenkyu Center | 抗酸化剤 |
JP2002315570A (ja) * | 2001-04-24 | 2002-10-29 | Yukito Akiyama | SOD様物質を生産するPhellinuslinteusの培養方法及びSOD様物質の製造方法 |
JP2003342198A (ja) * | 2002-05-29 | 2003-12-03 | Tadashi Goino | 賦形剤組成物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5466455A (en) * | 1990-10-18 | 1995-11-14 | Huffstutler, Jr.; Miles C. | Polyphase fluid-extraction process, resulting products and methods of use |
US20020136785A1 (en) * | 2000-11-07 | 2002-09-26 | Chun-Su Yuan | Ginseng berry extracts and pharmaceutical compositions from ginseng berry for the treatment of type 2 diabetes and obesity |
JP2002363092A (ja) * | 2001-06-01 | 2002-12-18 | Tadashi Goino | 抗高脂血症組成物及びその製造方法 |
JP3619189B2 (ja) * | 2001-12-26 | 2005-02-09 | チハヤ株式会社 | 食品組成物及び食品組成物の製造方法 |
AU2003202159A1 (en) * | 2002-04-08 | 2003-10-27 | Ginseng Science Inc. | Extract of processed panax genus plant, the preparation method thereof, and compositions containing the same |
US7977379B2 (en) * | 2002-05-15 | 2011-07-12 | Bhn Co., Ltd. | Method for angiogenesis inhibition or immunostimulation |
-
2005
- 2005-02-16 WO PCT/JP2005/002824 patent/WO2005077395A1/ja active Application Filing
- 2005-02-16 US US10/589,357 patent/US20070178118A1/en not_active Abandoned
- 2005-02-16 EP EP05710527A patent/EP1736206B1/en not_active Not-in-force
- 2005-02-16 DK DK05710527.2T patent/DK1736206T3/da active
- 2005-02-16 AT AT05710527T patent/ATE529119T1/de not_active IP Right Cessation
- 2005-02-16 CN CNA2005800051178A patent/CN1921871A/zh active Pending
- 2005-02-16 ES ES05710527T patent/ES2372696T3/es active Active
- 2005-02-16 JP JP2005518074A patent/JPWO2005077395A1/ja active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11292786A (ja) * | 1998-04-10 | 1999-10-26 | Tadashi Goino | 抗腫瘍活性を有する薬剤 |
JP2000143526A (ja) * | 1998-11-13 | 2000-05-23 | Asuke Yakuhin Kk | 田七人参、霊芝、アガリクス茸を主成分とする糖尿・高血圧・肝機能改善剤およびこれの製造方法 |
WO2001056589A2 (en) * | 2000-01-31 | 2001-08-09 | Tadashi Goino | Physiologically active compositions of basidiomycotina and araliaceae extracts |
JP2002000229A (ja) * | 2000-06-23 | 2002-01-08 | S F C:Kk | 健康食品 |
JP2002235084A (ja) * | 2001-02-08 | 2002-08-23 | Ishikawa Tennen Yakko Busshitsu Kenkyu Center | 抗酸化剤 |
JP2002315570A (ja) * | 2001-04-24 | 2002-10-29 | Yukito Akiyama | SOD様物質を生産するPhellinuslinteusの培養方法及びSOD様物質の製造方法 |
JP2003342198A (ja) * | 2002-05-29 | 2003-12-03 | Tadashi Goino | 賦形剤組成物 |
Non-Patent Citations (1)
Title |
---|
YAMAUCHI K. ET AL: "Tanshi Kinrui no Kosanka Sayo to sono Denki Kagakuteki Kento (Electrochemical Method for Estimating Antioxidative Activities of Fungi).", J.TECHNOLOGY AND EDUCATION., vol. 10, no. 2, 2003, pages 81 - 86, XP002995762 * |
Also Published As
Publication number | Publication date |
---|---|
CN1921871A (zh) | 2007-02-28 |
DK1736206T3 (da) | 2012-01-16 |
US20070178118A1 (en) | 2007-08-02 |
ATE529119T1 (de) | 2011-11-15 |
EP1736206A1 (en) | 2006-12-27 |
EP1736206A4 (en) | 2009-07-29 |
EP1736206B1 (en) | 2011-10-19 |
JPWO2005077395A1 (ja) | 2007-10-18 |
ES2372696T3 (es) | 2012-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104381996A (zh) | 蛹虫草片及其制备方法 | |
WO2005077395A1 (ja) | 生理活性組成物及びその製造方法 | |
CN107714794B (zh) | 俄色提取物片剂及其制备方法 | |
CN1143681C (zh) | 治疗糖尿病的药用组合物 | |
JP4896332B2 (ja) | 担子菌類とウコギ科植物の有効成分に基づく生理活性組成物 | |
KR20170116532A (ko) | 마카 및 대추야자, 영지버섯, 녹용 발효추출물을 유효성분으로 함유하는 운동수행능력 증진 및 피로회복 증진용 복합조성물 | |
CA2075077C (en) | Stevia extract-containing liquid internal medicine and method of preparing the same | |
Stengler | Health benefits of medicinal mushrooms | |
CN101283799A (zh) | 一种调整血脂的保健食品的制备方法 | |
KR20140125036A (ko) | 동충하초를 주성분으로 하는 건강보조식품 및 그의 제조방법 | |
CN1653923A (zh) | 蔷甘菌茶 | |
CN105963330B (zh) | 神秘果制剂及其应用 | |
KR100442766B1 (ko) | 코르다이세프스 큐슈엔시스 와이 코바야시의 인공 배양방법 및 그의 포자낭과의 용도 | |
JP4323128B2 (ja) | 生理活性組成物 | |
JP2009024027A (ja) | 生理活性組成物 | |
JP4245291B2 (ja) | 生理活性組成物及びその製造方法 | |
KR100522532B1 (ko) | 동충하초와 여주를 함유하는 혈당강하용 조성물 | |
RU2489039C2 (ru) | Биологически активная добавка к пище тонизирующего и адаптогенного действия | |
KR101911628B1 (ko) | 식물약재를 이용한 해독제의 제조방법 | |
KR100894029B1 (ko) | 인삼 꽃을 원료로 하는 당뇨의 예방을 위한 약학 조성물 및 치료를 위한 약학 조성물 | |
JP2005047814A (ja) | 血糖降下剤組成物 | |
RU2287998C2 (ru) | Средство для повышения работоспособности | |
KR20090053671A (ko) | 오가피와 비타민이 함유된 정제 및 그 제조 방법 | |
KR20190049093A (ko) | 대추잎 추출물, 또는 대추잎 및 가시오갈피의 혼합 추출물을 유효성분으로 함유하는 항진균용 조성물 | |
Talreja et al. | Journal of Global Trends in Pharmaceutical Sciences |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005518074 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580005117.8 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005710527 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10589357 Country of ref document: US Ref document number: 2007178118 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2005710527 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10589357 Country of ref document: US |